This week’s news from the life sciences includes Eli Lilly's investment in a Cambridge-Singapore biotech, Stealth ...

Unfortunately, many of our elected leaders today undervalue the role of patents to progress the science of drug discovery and ...

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Clea Shearer, star of the Netflix show “Get Organized with The Home Edit,” discussed her breast cancer journey after ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...

Eoneren/E+ via Getty Images Short interest for healthcare stocks in S&P 500 increased during September end vs.

Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...

Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...